

Final Minutes: February 15, 2001

Psychopharmacological Drugs Advisory Committee

Issue: NDA 20-91953: Zeldox™ (ZIPRASIDONE MESYLATE INTRAMUSCULAR, Pfizer, Inc.)

The meeting was held at the Holiday Inn in Gaithersberg, Maryland. Prior to the meeting, the members and consultants had reviewed background material from the FDA and from Lilly. There were approximately 150 persons in attendance.

Attendance:

PDAC Members Present: Carol Tamminga, M.D., Chair, , Robert Hamer, Ph.D., Tana Grady-Weliky, M.D., Richard P. Malone, M.D., Dan Oren, M.D., Irene Ortiz, M.D., Matthew Rudorfer, M.D.

PDAC Consultant: Michael Grundman, M.D.

PDAC Members Absent Edwin Cook, M.D, Gaurdia Banister, Ph.D.

Recused: Andrew Winokur, M.D, Abby Fyer, M.D.

FDA Participants: Russell Katz, M.D, Thomas Laughren, M.D.,

FDA Overview:

Tom Laughren highlighted the issues that the Agency was asking the committee to address. This was followed by a general discussion by the committee.

Overview of Pfizer's Presentations:

Rachel H. Swift, M.D., Executive Director, Pfizer Global Research & Development, CNS presented data on the **Efficacy Issues** of Zeldox. Edmund P. Harrigan, M.D., Vice President, Pfizer Global Research & Development, CNS, presented data on the **Safety Issues** of Zeldox.

Committee Discussion Specific to Safety and Efficacy for Zeldox™

1. Has the sponsor provided evidence from more than one adequate and well-controlled clinical investigation that supports the conclusion that (ziprasidone IM) is effective for the treatment of agitation from schizophrenia and schizo-affective disorders.

Yes = 8

No=0

There was some discussion about dose response. Many stated that the 10 and 20 mg doses looked similar enough although 20 mg was more robust. One member pointed out that the use of a 2mg dose (which was used to obtain IRB approval because IRBs would not approve a placebo control trial in the US for agitated psychotic persons) actually worked just like a placebo. Since they beat the 2 mg. dose and made the pre designated primary they had demonstrated efficacy.

2. Has the sponsor provided evidence that (ziprasidone IM) is safe when used in the treatment of agitation from schizophrenia and schizo-affective disorders?

Yes = 5

No=3


Those that felt that safety was not demonstrated were all concerned about the QTc issue; there was concern that a patient would be taking oral ziprasidone and then receive a 20 mg IM dose for agitation. A second IM dose could also be given shortly after if the patient remained agitated. Those that voted "no" did not believe that this could be addressed in the labeling and they felt that we needed data on higher dose trials such as 20 mg repeated use. (The above count for safety was derived from comments and not from a formal vote.)

A verbatim transcript of this meeting will be available on the FDA's Dockets Management Branch Website approximately 30 days after the meeting. The address is [HTTP://www.fda.gov/ohrms/dockets/ac/acmenu.htm](http://www.fda.gov/ohrms/dockets/ac/acmenu.htm).

I certify that I attended the February 15, 2001 meeting of the Psychopharmacologic Drugs Advisory Committee and that these minutes accurately reflect what transpired.

 2/15/01

Sandra Titus, Ph.D. Date
Executive Secretary, PDAC



Carol Tamminga, M.D. Date
Chair, PDAC

Prepared on Feb 15, 2001
Sandra Titus, Ph.D.